Top stocks to buy as we speak: Stock recommendations for May 13, 2025

JP Morgan is underweight on Dr Reddy’s Laboratories with the goal worth at Rs 1,060. Analysts mentioned the pharma main’s Jan-March income was in line, however EBITDA missed estimates. According to them the underweight ranking is premised on weak core EBITDA margins, lacklustre progress in India, lack of visibility on area of interest launches within the US and Semaglutide alternative might be first rate however the market is predicted to be aggressive.Citigroup has a buy ranking on Biocon with the goal worth at Rs 430. Analysts mentioned Biocon’s Jan-March numbers had been weak as ex-gRevlimid EBITDA margin declined. The firm additionally reported about 4% annual progress in biosimilars regardless of a powerful market share growth in onco property that signifies a weak pricing situation.Nomura has given a ‘buy’ ranking on Zydus Life with the goal worth at Rs 1,140. Analysts mentioned the corporate has acquired approval for gCopaxone, which they estimate has a market measurement of $600 million. Besides Teva, there are two generic gamers for the identical. They additionally count on further competitors in future from Biocon and Dr Reddy’s.Macquarie maintained its underperform ranking on Swiggy with the goal worth at Rs 260. Calling the Jan-March numbers ‘from bad to worse’, they mentioned Swiggy’s outcomes continued to under-score the challenges for the platform. The administration now expects contribution margin break even in 3-5 quarters versus prior steering of reaching the identical by December 2025. They additionally identified that the margin hole to Eternal (Zomato) continued to slim.Goldman Sachs has a buy ranking on Pidilite with the goal worth at Rs 3,475. Analysts mentioned the corporate’s robust, near-double digit quantity progress continued regardless of a muted setting. The administration is optimistic about FY26 progress given some enchancment within the broader consumption setting. They additionally really feel B2B progress possible to stay very robust over the following 2-3 years.Disclaimer: The opinions, analyses and recommendations expressed herein are these of brokerage and don’t replicate the views of The Times of India. Always seek the advice of with a professional funding advisor or monetary planner earlier than making any funding choices.